Compare SRPT & WD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRPT | WD |
|---|---|---|
| Founded | 1980 | 1937 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2000 | 2010 |
| Metric | SRPT | WD |
|---|---|---|
| Price | $22.03 | $40.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 29 | 4 |
| Target Price | $25.85 | ★ $76.00 |
| AVG Volume (30 Days) | ★ 2.9M | 420.3K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 5.34% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.99 | 0.55 |
| Revenue | ★ $2,198,237,000.00 | $1,234,306,000.00 |
| Revenue This Year | N/A | $20.60 |
| Revenue Next Year | N/A | $7.79 |
| P/E Ratio | ★ $7.22 | $73.24 |
| Revenue Growth | ★ 15.58 | 8.99 |
| 52 Week Low | $14.68 | $39.01 |
| 52 Week High | $25.32 | $90.00 |
| Indicator | SRPT | WD |
|---|---|---|
| Relative Strength Index (RSI) | 72.39 | 34.58 |
| Support Level | $20.12 | N/A |
| Resistance Level | $23.71 | $52.37 |
| Average True Range (ATR) | 1.08 | 1.51 |
| MACD | 0.33 | -0.08 |
| Stochastic Oscillator | 90.82 | 18.51 |
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
Walker & Dunlop Inc is a United States-based commercial real estate finance company. It is principally engaged in originating, selling, and servicing a number of multifamily and other commercial real estate financing products that are sold under the programs of Freddie Mac, Fannie Mae, Ginnie Mae, and the Federal Housing Administration. The company is managed based on three reportable segments: Capital Markets (CM), Servicing & Asset Management (SAM), and Corporate. The company generates a majority of its total revenue from gains from mortgage banking activities and servicing fees. It conducts business solely in the United States.